BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/20/2016 5:04:00 PM | Browse: 562 | Download: 868
Publication Name World Journal of Gastroenterology
Manuscript ID 18382
Country/Territory Turkey
2015-04-21 09:47
Peer-Review Started
2015-04-21 11:54
To Make the First Decision
2015-06-19 17:56
Return for Revision
2015-06-20 18:17
2015-07-02 07:10
Second Decision
2015-10-10 18:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2015-10-13 17:44
Articles in Press
2015-10-13 17:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
2015-11-05 06:07
Typeset the Manuscript
2016-01-07 16:10
Publish the Manuscript Online
2016-01-20 16:55
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Letter to the Editor
Article Title Treatment of chronic hepatitis B patients with tyrosine-methionine-aspartate-aspartate mutations
Manuscript Source Unsolicited Manuscript
All Author List Aylin Calica Utku and Oguz Karabay
Funding Agency and Grant Number
Corresponding author Dr. Aylin Calica Utku, Department of Infectious Diseases and Clinical Microbiology, Sakarya University Training and Research Hospital, Street of Adnan Menderes, 54200 Sakarya, Turkey. aylindoctor@hotmail.com
Keywords Hepatitis B; Lamivudine; Tyrosine-methionine-aspartate-aspartate mutation; Drug resistance; Treatment
Core Tip Lamivudine is a nucleoside analogue that has been used in treatment of chronic hepatitis B. The only drawback of lamivudin is drug resistance during the treatment. Entecavir and tenofovir are potent hepatitis B virus inhibitors with a high barrier to resistance . They can used as first-line monotherapies. The main problem of lamivudine treatment is development of mutation in the tyrosine-methionine-aspartate-aspartate (YMDD) motif. Treatment with lamivudine may cause exacerbation of hepatitis in patients with YMDD mutation. These patients should use YMDD mutant form-effective drugs.
Publish Date 2016-01-20 16:55
Citation Calica Utku A, Karabay O. Treatment of chronic hepatitis B patients with tyrosine-methionine-aspartate-aspartate mutations. World J Gastroenterol 2016; 22(4): 1727-1728
Url http://www.wjgnet.com/1007-9327/full/v22/i4/1727.htm
DOI http://dx.doi.org/10.3748/wjg.v22.i4.1727
Full Article (PDF) WJG-22-1727.pdf
Full Article (Word) WJG-22-1727.doc
Manuscript File 18382-Review.doc
Answering Reviewers 18382-Answering reviewers.pdf
Audio Core Tip 18382-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 18382-Conflict-of-interest statement.pdf
Copyright License Agreement 18382-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 18382-Language certificatent.pdf
Peer-review Report 18382-Peer-review(s).pdf
Scientific Misconduct Check 18382-Scientific misconduct check.pdf
Scientific Editor Work List 18382-Scientific editor work list.pdf